Grace Therapeutics Inc. (NASDAQ: GRCE) presented results from its phase 3 STRIVE-ON safety trial of GTx-104 at the 2025 Neurocritical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE